SAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit services, today announced that it is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz, for new patients requiring medication for inflammatory conditions such as Crohn’s disease or rheumatoid arthritis.

圣地亚哥——（商业新闻短讯）——美国最大的健康解决方案、技术和药房福利服务独立提供商MedImpact Healthcare Systems，Inc.今天宣布，它正在扩大Humira生物仿制药、Simlandi和阿达木单抗adaz的使用范围，用于需要治疗克罗恩病或类风湿性关节炎等炎症疾病的新患者。

Patients already taking Humira through their pharmacy benefit can continue to do so, and new patients who have taken one of the two biosimilars but did not see the desired results may switch to Humira..

已经通过药房福利服用Humira的患者可以继续这样做，服用两种生物仿制药之一但没有看到预期结果的新患者可能会改用Humira。。

“We are making these biosimilars for Humira available through the pharmacy benefit because we are now, for the first time, satisfied that they meet our stringent standards for clinical interchangeability and lowest net cost,” said Nicole Ellermeier, PharmD, MBA, Vice President Formulary Strategy & Rebate Economics, MedImpact.

“我们正在通过药房福利提供这些用于Humira的生物仿制药，因为我们现在首次对它们满足我们严格的临床互换性和最低净成本标准感到满意，”MedImpact处方集策略与回扣经济学副总裁，医学博士，MBA Nicole Ellermeier说。

“And we have designed our approach to give members, providers, and payers flexibility, choices, and confidence.”.

“我们设计了我们的方法，为会员、提供商和付款人提供灵活性、选择和信心。”。

MedImpact’s approach to biosimilars announced today is consistent with its 35-year tradition of pharmacy and manufacturer neutrality. Members may have their prescriptions filled at any pharmacy for FDA-approved biosimilars, regardless of the manufacturer. This level of flexibility is not universally available in the marketplace.

MedImpact今天宣布的生物仿制药方法符合其35年的制药和制造商中立传统。会员可以在FDA批准的生物仿制药的任何药房填写处方，无论制造商如何。这种程度的灵活性在市场上并不普遍。

Given the complexity of the manufacturing process and nature of the ingredients, MedImpact is making two biosimilars available to ensure availability in the event of supply chain disruptions..

鉴于制造过程的复杂性和成分的性质，MedImpact正在生产两种生物仿制药，以确保供应链中断时的可用性。。

To ensure that clinical considerations take precedence over cost alone, the member copay, deductible, and other factors will be the same for the biosimilars and Humira. This allows member flexibility without incurring any additional out-of-pocket costs.

为了确保临床考虑优先于单独的成本，生物仿制药和Humira的成员费用，免赔额和其他因素将是相同的。这使会员具有灵活性，而不会产生任何额外的自付费用。

MedImpact continues to monitor the market for biosimilars for several conditions and will to add to its formularies others that meet its clinical, supply chain, and cost requirements.

MedImpact继续监测生物仿制药市场的几种情况，并将增加其他符合其临床，供应链和成本要求的处方集。

“Expanding access to biosimilars is complex and involves significant clinical and economic implications,” said Arpit Patel, PharmD, Vice President, Trade Relations, MedImpact. “Our guiding principle, however, is straightforward: First, we must provide convenient and affordable access to clinically appropriate medications, followed by ensuring these medications are financially sustainable for patients and payers alike.”.

MedImpact贸易关系副总裁Arpit Patel说：“扩大生物仿制药的使用是复杂的，涉及重大的临床和经济影响。”。。

About MedImpact Healthcare Systems

关于MedImpact医疗保健系统

San Diego-based MedImpact Healthcare Systems, Inc. is the nation’s largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs.

总部位于圣地亚哥的MedImpact Healthcare Systems，Inc.是美国最大的独立健康解决方案、技术和药房福利管理提供商。35年来，MedImpact一直帮助商业和政府医疗保健付款人改善会员健康状况，管理福利并降低药品成本。

To learn more, visit us online, follow us on LinkedIn, or contact us at info@MedImpact.com..

要了解更多信息，请在线访问我们，在LinkedIn上关注我们，或通过info@MedImpact.com..